Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
116 participants
INTERVENTIONAL
2009-03-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* increases immune responses
* decreases inflammatory status
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to evaluate whether coffee consumption improves immune and inflammatory status in healthy elderly subjects. To sort out the role of antioxidants, we will test 2 different soluble coffee, i.e. fully torrefied coffee and partially torrefied coffee.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No coffee
No interventions assigned to this group
Group 1
Fully torrefied coffee
Fully torrefied coffee
Fully torrefied coffee
Group 2
Partially torrefied coffee
Partially torrefied coffee
Partially torrefied coffee
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fully torrefied coffee
Fully torrefied coffee
Partially torrefied coffee
Partially torrefied coffee
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having the ability to comprehend the procedures of the study
* Having obtained his/her informed consent after verbal and written information
Exclusion Criteria
* Subjects with rapidly deteriorating health status at enrolment in the study
* Subjects with terminal or acute disease, or unstable health status
* Subjects with chronic disease: chronic respiratory illness; chronic diseases of the pulmonary or cardiovascular systems (including asthma); chronic metabolic disease (diabetes); chronic renal disease, organ failure
* Subjects with serious neurological disorder, including dementia (MMSE \< 20) or Alzheimer's disease
* Subjects who have experienced rapid weight loss, chronic diarrhea (loose stools, 3 times daily), or Crohn's (IBD)
* Subjects with gastrointestinal problems
* Subjects with a hospitalization planned during this study
* Subjects who have received any antibiotic treatment during the last 3 months prior to the beginning of this study
* Subjects who had a colonoscopy performed during the last 3 months prior to the beginning of this study
* Subjects with immune deficiency diseases (e.g. HIV infection)
* Subjects with a history of allergy - especially to egg protein, egg, shellfish or the antibiotics polymyxin or neomycin
* Subjects receiving medication that may influence the immune system (i.e. corticosteroids, immuno-suppressors and immuno-modulators, antimicrobials)
* Subjects who have received any vaccination during the last 15 days prior to baseline
* Subjects who are expected to be non-compliant
* Subjects currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study
* Subjects participating in another research study involving any type of medication related to the study
65 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
University of Chile
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Bunout
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Bunout, MD
Role: PRINCIPAL_INVESTIGATOR
INTA University of Chile, Santiago, Metropolitana, Chile
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INTA University of Chile
Santiago, Santiago Metropolitan, Chile
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Web site of INTA University of Chile
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
immunecoffee
Identifier Type: -
Identifier Source: org_study_id